Genasense: GNTA and partner Aventis S.A. (AVE, Strasbourg, France) decided to increase the size of the Phase III melanoma trial from 450 to 750 patients. GNTA s

Genta Inc. (GNTA), Berkeley Heights, N.J.
Product: Genasense
Business: Cancer
Therapeutic category: Apoptosis, Antisense
Target: Bcl-2

Read the full 163 word article

How to gain access

Continue reading with a
two-week free trial.